Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices
Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Sept. 18, 2025. Document 2025-18082. Updated Nov. 19, 2026.
- What it does
The Food and Drug Administration (FDA) is issuing a final order reclassifying qualitative hepatitis B virus (HBV) antigen assays (product code LOM), HBV antibody assays (product code LOM), and quantitative HBV nucleic acid-based assays (product code MKT), all of which are postamendments class III devices, into class II (special controls), subject to premarket notification. FDA is also establishing the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of these device types.
The Food and Drug Administration's summary, as published in the Federal Register.
- What changed in the regulation
1 part of Title 21 of the Code of Federal Regulations:
Wording on eCFR: the day before it took effect and from the day it took effect (first part listed).
- Compared with
The Food and Drug Administration has published 103 final rules in 2026 so far, compared with 68 in all of 2025.
Counted by the Tribune from Federal Register records since Jan. 1, 2025.
- What happens next and when
This order is effective October 20, 2025. See further discussion in Section IV, "Implementation Strategy."
The agency's dates, word for word.
The record as published
| Document number | 2025-18082 |
|---|---|
| Action | Final amendment; final order. |
| Agencies | Health and Human Services Department; Food and Drug Administration |
| Published | Sept. 18, 2025 |
| Effective date | Oct. 20, 2025 |
| Docket | FDA-2024-N-3533 |
Source: the Federal Register (public domain). The document in the Federal Register